Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout [Yahoo! Finance]
SOPHiA GENETICS SA - Ordinary Shares (SOPH)
Company Research
Source: Yahoo! Finance
Powered by the Swiss data company's genomic analysis platform, SOPHiA DDM, MSK-ACCESS is a decentralised version of a liquid biopsy test developed by the Memorial Sloan Kettering Cancer Center (MSK). SOPHiA DDM gained a CE mark under the EU's revised In Vitro Diagnostics Regulation (IVDR) last month. Sophia Genetics, AZ, and MSK first announced a partnership, intended to address global cancer care inequalities with the rollout of MSK-ACCESS powered by Sophia DDM, in October 2023. Upon the initial launch of MSK-ACCESS powered by SOPHiA DDM in April 2024, 14 global healthcare institutions signed on to adopt or pilot the application. Under the latest step in the collaboration, AZ will now support the rollout of MSK-ACCESS to 20 global locations over the next 12 months. In liquid biopsy testing, cell-free DNA (cfDNA) is isolated to detect circulating tumour DNA (ctDNA), providing a less invasive cancer diagnostic method to solid tumour testing, which is not always possible due
Show less
Read more
Impact Snapshot
Event Time:
SOPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOPH alerts
High impacting SOPHiA GENETICS SA - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
SOPH
News
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS SA (NASDAQ: SOPH) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
SOPH
Earnings
- 11/5/24 - Miss
SOPH
Sec Filings
- 1/27/25 - Form 144
- 1/27/25 - Form 144
- 1/24/25 - Form 144
- SOPH's page on the SEC website